Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Sep 1;116(17):4000-6.
doi: 10.1002/cncr.25197.

Population-based analysis of occult primary breast cancer with axillary lymph node metastasis

Gary V Walker  1 , Grace L Smith, George H Perkins, Julia L Oh, Wendy Woodward, Tse-Kuan Yu, Kelly K Hunt, Karen Hoffman, Eric A Strom, Thomas A Buchholz
Affiliations

Population-based analysis of occult primary breast cancer with axillary lymph node metastasis

Gary V Walker et al. Cancer. .

Abstract

Background: Single-institution data suggest that treatment with radiation and axillary lymph node dissection (ALND) may be an appropriate alternative to mastectomy for T0N+ breast cancer. Population-based multi-institutional data supporting this approach are lacking.

Methods: The cause-specific survival (CSS) and overall survival (OS) of women with T0N+M0 ductal, lobular, or mixed breast cancer in the Surveillance, Epidemiology, and End Results database from 1983 to 2006 were analyzed. Groups were defined as: 1) no ALND, mastectomy, or RT (observation); 2) ALND only; 3) mastectomy plus ALND with or without postmastectomy radiation (Mast); and 4) breast-conserving therapy (BCT) with ALND and radiation (BCT).

Results: In total, 750 of 770,030 patients with breast cancer had T0N+M0 disease (incidence, 0.10%), and 596 of those patients underwent ALND (79.5%). Patients who underwent Mast or BCT (n = 470) had a 10-year OS rate of 64.9% compared with 58.5% for patients who underwent ALND only (n = 126; P = .02) and 47.5% for patients who underwent observation only (n = 94; P = .04). The 10-year CSS rate was 75.7% for patients who underwent BCT versus 73.9% for patients who underwent Mast (P = .55). In multivariate analysis of CSS for patients who underwent Mast or BCT, the following factors were correlated with an unfavorable outcome: positive estrogen receptor status (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.24-0.96; P = .04), >/=10 positive lymph nodes (HR, 5.7; 95%CI, 2.4-13.4; P </= .01), and <10 resected lymph nodes (HR, 42.9; 95%CI, 1.2-7.1; P = .02). Mast did not improve CSS compared with BCT (HR, 1.09; 95%CI, 0.57-2.1; P = .79).

Conclusions: Definitive locoregional treatment with either Mast or BCT improved the outcome of patients with T0N+breast cancer, and no difference in survival was observed between the treatments. Cancer 2010. (c) 2010 American Cancer Society.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

The authors made no disclosures.

Figures

Figure 1
Figure 1
This Kaplan-Meier curve illustrates overall survival for patients who underwent breast-conserving therapy (BCT) or mastectomy (Mast) (green line); axillary lymph node dissection (ALND) (red line); and no ALND, Mast, or radiation therapy (RT) (blue line).
Figure 2
Figure 2
This Kaplan-Meier curve illustrates cause-specific survival for patients who underwent breast-conserving therapy (BCT) (red line) and patients who underwent mastectomy (Mast) (blue line).
Figure 3
Figure 3
This Kaplan-Meier curve illustrates overall survival for patients who underwent breast-conserving therapy (BCT) (red line) and patients who underwent mastectomy (Mast) (blue line).
See this image and copyright information in PMC

References

    1. National Comprehensive Cancer Network (NCCN) NCCN Clinical Practice Guidelines in Oncology, Breast Cancer v1.2009. [Accessed August 28, 2009]; Available at: http://www.nccn.org/professionals/physician_gls/PDF/breast.pdf.
    1. Vlastos G, Jean ME, Mirza AN, et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8:425–431. - PubMed
    1. Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47:143–147. - PubMed
    1. Shannon C, Walsh G, Sapunar F, A’Hern R, Smith I. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11:414–418. - PubMed
    1. Zippin C, Lum D, Hankey BF. Completeness of hospital cancer case reporting from the SEER Program of the National Cancer Institute. Cancer. 1995;76:2343–2350. - PubMed